Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.
Cytos Biotechnology AG is developing an intramuscular therapeutic vaccine, CYT-002-NicQb (also known as nicotine-Qbeta), based on its Immunodrug (formerly known as alpha vaccine) nicotine-specific antibody-generating technology, for the potential treatment of nicotine addiction. A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007.
Heading
Christine E
CE
The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK. moore11@globalnet.co.uk
D002986:Clinical Trials as Topic; D006801:Humans; D007273:Injections, Intramuscular; D009538:Nicotine / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000379:methods; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D014612:Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*
D014612:Vaccines; C519280:nicotine Qbeta vaccine; D009538:Nicotine